AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis

Current Opinion in Investigational Drugs

Volumn 10, Issue 11, 2009, Pages 1236-1242

  Nazarian, R ^a   Weinberg, J M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AN 2728; ANTIINFLAMMATORY AGENT; BETAMETHASONE; CALCINEURIN INHIBITOR; CORTICOSTEROID; DEXAMETHASONE; INTERLEUKIN 12; INTERLEUKIN 23; PHOSPHODIESTERASE IV INHIBITOR; PIMECROLIMUS; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; ATROPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; EDEMA; ERYTHEMA; GINGIVITIS; HUMAN; INJECTION SITE REACTION; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN BURNING SENSATION; SKIN IRRITATION; STRIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; CLINICAL TRIALS AS TOPIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYTOKINES; DERMATITIS, ATOPIC; HUMANS; INFLAMMATION; PHOSPHODIESTERASE INHIBITORS; PSORIASIS;

EID: 70449368604     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Therapeutic beneft of PDE4 inhibitors in infammatory diseases. Dastidar SG, Rajagopal D, Ray A CURR OPIN INVESTIG DRUGS 2007 8 5 364-372
2. Pipeline: AN-2728. Anacor Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2008 March 26
3. AN2728, a novel oxaborole in development for treatment of psoriasis, demonstrates signifcant activity in a micro plaque study. Beutner K, Gassmueller I, Marti D, Lathrop A J INVEST DERMATOL 2008 128 Suppl 1 Abs 367
4. Anacor pipeline. Anacor Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2008 May 28
5. Structure-activity studies of AN2728 and AN2898, novel oxaborole compounds with anti-infammatory activity. Akama T, Freund Y, Kimura R, Baker SJ, Zhang Y-K, Hernandez V, Zhou H, Sanders V, Maples K, Plattner J INT INVESTIGATIVE DERMATOL 2008 128 Suppl 1 Abs P88
6. Chapter 18: Psoriasis. Gudjonsson JE, Elder JT FITZPATRICKS DERMATOL GENERAL MED (EDS: WOLFF K, GOLDSMITH LA, KATZ SI, GILCHREST BA, PALLER A, LEFFEL DJ) 2007 McGraw-Hill, New York, NY, USA 7th Edition 169-193
7. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR et al J AM ACAD DERMATOL 2008 58 5 826-850
8. Anacor announces positive results from phase 2 psoriasis trial. Anacor Pharmaceuticals Inc PRESS RELEASE 2009 February 19
9. AN2728 preclinical studies demonstrate an acceptable safety profle for the topical treatment of psoriasis and atopic dermatitis. Heyman I, Ip E, Maples K, Liu L J AM ACAD DERMATOL 2009 60 3 Suppl Abs P3357
10. AN2728 demonstrates signifcant effcacy in three phase Ib psoriasis microplaque trials. Beutner K, Lathrop A, Marti D, Gassmueller J J AM ACAD DERMATOL 2009 60 Suppl 3 Abs 3327
11. AN2728 demonstrates signifcant safety and effcacy in a phase IIa double-blind trial in plaque type psoriasis. Beutner K, Lathrop A, Marti D, Zane L, Toledo M J AM ACAD DERMATOL 2009 60 Suppl 3 Abs 3328
12. Discovery and structure-activity study of a novel benzoxaborole anti-infammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ BIOORG MED CHEM LETT 2009 19 8 2129-2132
13. In vitro activity and mechanism of action of AN2728, a novel oxaborole in development for treatment of psoriasis. Freund Y, Alley MK, Kimura R, Rock F, Akama T, Sanders V, Zhou Y, Maples K, Plattner J J INVEST DERMATOL 2008 128 Suppl 1 Abs 89
14. Preclinical toxicology of AN2728, a novel oxaborole in development for the topical treatment of psoriasis. Heyman I, Ip E, Liu L, Sanders V, Maples K J INVEST DERMATOL 2008 128 Suppl 1 Abs P84
15. Discovery of novel boron containing compounds as dual inhibitors of TNF-? and IL-23 release. Akama T, Sanders V, Graves G, Lu X, Sharma R, Sales M, Kimura R, Antunes J, Dong C, Freund Y, Nieman J et al WORLD CONGR INFLAMM 2009 9 Abs GA10.9 (O/P)
16. Preclinical toxicology of AN2728, a novel borinic acid ester with anti-infammatory activity. Ip E, Bellinger-Kawahara C, Heyman I, Maples K J AM ACAD DERMATOL 2007 56 2 Abs P2756
17. Medicinal chemistry development of AN2728, a novel oxaborole in development for the topical treatment of psoriasis. Baker S, Sanders V, Akama T, Plattner J J AM ACAD DERMATOL 2007 56 2 Abs P2703
18. Skin penetration and anti-infammatory activity of AN2728, a novel oxaborole. Ip E, Baker S, Hold K, Maples K J AM ACAD DERMATOL 2007 56 2 Abs P2712
19. AN2728, a novel borinic acid ester with broad-spectrum in vitro anti-infammatory activity. Freund YR, Bellinger-Kawahara C, Kimura R, Pinto B J AM ACAD DERMATOL 2007 56 2 Abs P421
20. Anacor Pharmaceuticals Inc company world wide website and pipeline. Anacor Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2009 August 27
21. AN2728 ointment, a novel oxaborole with anti-infammatory activity, demonstrates safety and signifcant effcacy in a phase Ib psoriasis plaque test. Zane LT, Gassmueller J, Fluhr J, Marti DK, Lathrop A, Beutner KR MONTAGNA SYMP BIOL SKIN 2008 57 Abs PSR-102
22. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Baeumer W, Hoppmann J, Rundfeldt C, Kietzmann M INFLAMM ALLERGY DRUG TARGETS 2007 6 1 17-26
23. Biological drugs targeting the immune response in the therapy of psoriasis. Pastore S, Gubinelli E, Leoni L, Raskovic D, Korkina L BIOLOGICS 2008 2 4 687-697
24. Research and markets: The biologics created $1.4 billion in psoriasis sales in 2008 across the seven major markets, contributing 55% of the $2.5 billion psoriasis market. Research and Markets PRESS RELEASE 2009 September 03
25. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Prodanovich S, Kirsner RS, Kravetz JD, Ma FC, Martinez L, Federman DG ARCH DERMATOL 2009 145 6 700-703
26. Topical treatment of psoriasis. Kamili QU, Menter A CURR PROBL DERMATOL 2009 38 37-58
27. Dermoscopic assessment of long-term topical therapies with potent steroids in chronic psoriasis. Vazquez-Lopez F, Marghoob AA J AM ACAD DERMATOL 2004 51 5 811-813
28. The role of topical vitamin D modulators in psoriasis therapy. Tanghetti EA J DRUGS DERMATOL 2009 8 8 Suppl S4-S8
29. Management of psoriasis: The position of retinoid drugs. Arechalde A, Saurat JH BIODRUGS 2000 13 5 327-333
30. Retinoids and phototherapy for psoriasis. Monfrecola G, Baldo A J RHEUMATOL SUPPL 2009 83 71-72
31. Effcacy and safety of fumaric acid esters in the long-term treatment of psoriasis - A retrospective study (FUTURE). Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T J DTSCH DERMATOL GES 2009 7 7 603-610
32. Treatment options for atopic dermatitis. Buys LM AM FAM PHYS 2007 75 4 523-528
33. Practice of phototherapy in the treatment of moderate-to-severe psoriasis. Nguyen T, Gattu S, Pugashetti R, Koo J CURR PROBL DERMATOL 2009 38 59-78
34. Guidelines of care for the management of psoriasis and psoriatic arthritis section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JYM, Lebwohl M, Lim HW, Van Voorhees AS et al J AM ACAD DERMATOL 2009 61 3 451-485
35. Chapter 14: Atopic dermatitis. Leung DYM, Eichenfeld L, Boguniewicz M FITZPATRICKS DERMATOL GENERAL MED (EDS: WOLFF K, GOLDSMITH LA, KATZ SI, GILCHREST BA, PALLER A, LEFFEL DJ) 2007 McGraw-Hill, New York, NY, USA 7th Edition 146-158